Generali Asset Management SPA SGR raised its holding in Illumina by 51.6% during the third quarter, adding 7,574 shares to reach a total of 22,249 shares valued at approximately 2.11 million. This increase underscores the firm’s confidence in Illumina’s life sciences sequencing platforms, bringing its cumulative investment to one of its largest single–security allocations. Institutional ownership in Illumina stands at 89.42%, highlighting continued interest from professional money managers across the biotechnology sector.

In the quarter ended October 30, Illumina reported non-GAAP earnings per share of 1.34, beating consensus by 0.18, on revenues of 1.08 billion, slightly ahead of estimates. Return on equity reached 29.21% and net margin was 16.40%, with year-over-year revenue growth of 0.4%. The company’s balance sheet remains solid, with a current ratio of 1.43, quick ratio of 1.12 and debt-to-equity of 0.42. Management has guided full-year EPS to a range of 4.65–4.75, compared with analysts’ consensus of 4.51.

Director Scott Gottlieb added 500 shares at an average cost of 122.13 per share, increasing his stake by 4.16%, while EVP Scott M. Davies sold 323 shares for proceeds totaling 43,957, reducing his position by 1.77%. Analysts remain cautiously optimistic: Evercore ISI and Canaccord raised their targets to 142 and 130 respectively, both maintaining outperform or hold recommendations; Zacks downgraded to hold. Overall consensus comprises five buy ratings, fourteen holds and two sells, reflecting a moderate investor outlook on Illumina’s growth trajectory.